TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05564416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study: NCT04986865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-101
Description: ATG-101 will be administered intravenously once every 21 days. During the Escalation Phase, the dose levels will be determined by the starting dose and the escalation steps taken in the trial. The Dose Expansion Phase will begin at the defined MTD, RP2D, or biologically optimal dose.
Study: NCT05358236

Intervention type: OTHER
Group type: OTHER
Intervention: Episiotomy Wound Care and Genital Hygiene Training
Description: Episiotomy wound healing and genital hygiene training were given face-to-face by researchers to the mothers assigned to the training group. The trainings were given to each mother individually in their rooms. The total training lasted an average of one hour. At the end of the training, the mothers were given a written and illustrated training brochure.~Training content~* Primarily, external reproductive organs were shown to mothers through pictures.~* Urethra, Vagina, Anus, Perineum areas were mentioned.~* The definition of Episiotomy was made; and where and how it was applied was explained with visual materials. It was explained how to care for the episiotomy area to heal more rapid and healthier.~* Information was given on how to change their menstrual pads.~* Information was provided on what to look for when using underwear~* What to watch out while taking a bath:~* What to pay attention to in your stitch area
Study: NCT05985954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given by PO
Study: NCT05564416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05375851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Interventions
Description: The digital interventions will consist of two parts:~A) Psychoeducation videos: Five psychoeducation videos on mental health and GAD will be produced especially for the research to be watched by the patient between consultations. These videos will last approximately 3 minutes, will use animations and educational content. They will be available on +PSI app. The topics of the videos will be as follows: Normal Anxiety versus Pathological Anxiety; Sleep Hygiene; Healthy Eating and Mental Health; Physical Exercise and Mental Health; Excessive Consumption of Alcohol and Drugs.~B) GAD-7 Scale: The patient will be instructed to respond to the GAD-7 self-administered scale the day before their next scheduled appointment. This instrument will also be available free of charge on +PSI mobile app and will be used to guide clinical management.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The usual treatment will be standardized as follows:~Biweekly online consultations (via WhatsApp or Google Meet) previously scheduled, 20/30 minutes-long, with a trained psychiatrist.~The patient will receive only clinical, not psychotherapeutic treatment. The psychiatrist will be instructed to perform an assessment of symptoms, general guidelines on the pathology, use of medication when necessary.~The medication of choice, when necessary, will be fluoxetine, as it is the medication for the treatment of GAD available free of charge in our health system in Brazil.
Study: NCT06442033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity stationary cycling
Description: All community based exercise sessions are: 3x/week for 40 min, which includes a 5-min warm up \& cool down and a 30-minute main exercise set. Exercise parameters will be set by a neurologically trained physical therapist and will be progressed over time with the ultimate goal of the individual reaching moderate-vigorous exercise. Moderate-vigorous exercise for this project is defined as a cadence of 75+ rpms and a target HR of 60-80% of their age-predicted max
Study: NCT05841186

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of pegfilgrastim administration
Description: Timing of pegfilgrastim administration

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of pegfilgrastim administration
Description: Timing of pegfilgrastim administration

Intervention type: OTHER
Group type: OTHER
Intervention: Timing of pegfilgrastim administration
Description: Timing of pegfilgrastim administration
Study: NCT05829694

Intervention type: OTHER
Intervention: Parental Status
Description: The aim of the study is to assess the impact parenthood has on health outcomes.
Study: NCT06409533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Patients diagnosed with atrial fibrillation due to moderate to severe rheumatic mitral stenosis (AF-RMS) and undergoing treatment will receive care in accordance with the PERKI (Indonesian Heart Association) guidelines for Atrial Fibrillation. The selection and titration of rate control medications, including β-blockers, digoxin, or their combination, will be managed by the attending cardiologists (care providers) to achieve the target rate control.
Study: NCT05141019

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Panel-based pharmacogenetic genotyping
Description: After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panel-based pharmacogenetic genotyping
Description: After providing consent, subjects will be randomized to receive either the immediate pharmacogenetic testing arm or the delayed arm. Subjects in both groups will provide a DNA sample by saliva, buccal cell, or blood at study enrollment. Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and will have their results entered into their electronic health record (EHR) and provided to them within 2-4 weeks. Subjects assigned to the delayed pharmacogenetic genotyping group will also be tested, but their results will not be released until after their participation in the study has ended. Subjects in each arm will complete surveys and questionnaires regarding their medication satisfaction, as well as their healthcare utilization use at baseline and then again at 6- and 12-months. Implementation-specific questions will also be asked to assess the feasibility and sustainability of the intervention as well as assessments of intervention fidelity and adaptations.
Study: NCT06467825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Supplement
Description: Participants will be given a potassium supplement that will help prevent low blood potassium levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Supplement
Description: Participants will be given a potassium supplement that will help prevent low blood potassium levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 20 MG
Description: Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 20 MG
Description: Furosemide (Lasix, 20 mg) will be administered through IV catheter to induce urination. The goal of this procedure is to reduce the volume of plasma in the blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Garment
Description: From the torso and leg measurements obtained during Visit 1A, a custom-designed compression garment will be constructed.
Study: NCT05933941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: This is a game set in space in which you pilot a spaceship and have to go through rings while dodging meteorites, all controlled by neck movements. Before starting the game, the assigned therapist is in charge of establishing the necessary movement parameters. In addition, the software allows you to modify the difficulty of the game. We will start the first 3 sessions in easy mode, where cervical mobility does not exceed 30º. The following 3 sessions will be configured in medium mode, reaching 60º of mobility. In the last 2 sessions, we will select the hard mode, which not only increases the speed of the spacecraft but also covers the entire range of cervical mobility.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: The patients perform mobility and strengthening exercises for the cervical region, in which they are required to complete 1 set of 10 repetitions for each exercise. The patient should rest for at least 30 seconds between exercises.
Study: NCT04758351

Intervention type: OTHER
Intervention: Usual clinical practice
Description: Based on European Respiratory Society guidelines on management for chronic cough.
Study: NCT06409169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS TaT
Description: Dried Blood Spot (DBS) testing for HCV DCHEQ and Baseline Surveys If at high risk for liver fibrosis, blood draw prior to treatment initiation If low risk for liver fibrosis, Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Point-of-care or DBS testing for HCV Blood draw to test liver fibrosis DCHEQ and Baseline Surveys Telemedicine visit with PATHS provider HCV treatment initiation Transient elastography (TEG)
Study: NCT06379659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growh hormone
Description: In this group, patients will receive growth hormone solution containing 1.99 milligrams of the drug dissolved in 1.5 milliliters of 0.9% saline solution (normal saline), in addition to standard hormonal therapy, starting from cycle day 10. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, growth hormone infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to the intervention group, from cycle day 10, an equal volume of 0.9% saline solution (normal saline) will be administered in addition to standard hormonal therapy. Treatment sessions will be conducted at two-day intervals. In case of non-response to treatment (failure to reach a minimum endometrial thickness of 7 millimeters in the subsequent assessment), the patient will receive a maximum of 4 doses, and if response to treatment is observed, placebo infusion will be discontinued. All infusions will be administered intrauterinely via an Intrauterine Insemination (IUI) catheter.
Study: NCT06218277

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ASTAR
Description: Rapid AST with ASTAR
Study: NCT05442554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Brentuximab vedotin IV infusion.
Study: NCT06019754

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: one point combined Lumbar and sacral plexus block
Description: performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: one point combined Lumbar and sacral plexus block
Description: performing an ultrasound-guided one-point combined Lumbar and sacral plexus block using a one-point puncture. Block success will be assessed using the perfusion index (PI) before and after performing the block
Study: NCT06371612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Parental Presence

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive Remover Spray
Description: Parental Presence + an alcohol-free silicone-based aresol spray for medical use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ball Squeezing + Adhesive Remover Spray
Description: Parental Presence + an alcohol-free silicone-based aresol spray for medical use + squeezing the stress ball
Study: NCT06088992

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG004
Description: Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.
Study: NCT06560489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.
Description: This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
Study: NCT06327945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung uDCD Protocol
Description: The intervention is initiation of PEEP and supplemental oxygen, without requiring prior permission (e.g., for cases not having first person authorization for organ donation and organ donation for research), to offer lung donation opportunities for cases which would otherwise be ineligible in the U.S.
Study: NCT04769479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acoramidis
Description: acoramidis
Study: NCT05371886

Intervention type: OTHER
Group type: OTHER
Intervention: Dose-effect relationship of morphine +/- midazolam administration
Description: Dose-effect relationship of morphine +/- midazolam administration as continuous infusion in neonates undergoing mechanical ventilation through PKPD modelling
Study: NCT05960097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0701 Bivalent High dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0701 Bivalent Medium dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0701 Bivalent Low dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0601 Monovalent High dose
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control vaccine
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0801 Monovalent
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0801 Monovalent
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0801 Monovalent
Description: Study vaccine is administered as a single intramuscular injection in the deltoid area on Day 1.
Study: NCT05614531

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EXG001-307 injection
Description: non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EXG001-307 injection
Description: non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EXG001-307 injection
Description: non-replicating, rAAV vector based on AAV9 containing cDNA encoding the human SMN protein.
Study: NCT05507723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treat-to-target
Description: Treatment to achieve urate target using supported self-management approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment escalation by GP based on usual clinical practice
Study: NCT05135702

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Propionate
Description: a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: a 500 mg powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: a color, size, calorie, and consistency-matched powder dietary supplement that can be mixed into food or drinks. It will be taken twice daily for four weeks.
Study: NCT04689139

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample tests for determination of biomarkers levels
Description: Using of proadrenomedullin, presepsin, NT-proBNP, Troponin I to determine the correlation of perioperative complications.
Study: NCT05464667

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Dose Escalation: 5 Cohorts - 30 GY in 5 fractions (baseline treatment with 0 boost dose to GTV), 35, 40, 45, 50 Gy in 5 fractions (Part 1)~Dose Expansion: Maximum Tolerated Dose determined during dose escalation (Part 2)
Study: NCT05521607

Intervention type: DEVICE
Group type: OTHER
Intervention: Picterus Jaundice Pro (JP)
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study: NCT06072794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VL-PX10
Description: VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
Study: NCT06376253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-EVS459
Description: Radioligand imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-EVS459
Description: Radioligand therapy